20
Jun

Sanofi is breaking it off with oncology partner Merrimack Pharmaceuticals, handing back full rights to MM-121, a treatment that has three times failed to hit the mark in midstage studies.

…read more

Source: After three strikes, Sanofi gives up on Merrimack’s cancer drug

    

0 No comments